Selank Peptide

## What it is Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in collaboration with the V. V. Zakusov Institute of Pharmacology in the early 1990s. The molecule is a stabilized analog of tuftsin, an endogenous tetrapeptide derived from the IgG heavy chain that has documented immunomodulatory and behavioral activity. The Pro-Gly-Pro tail extends the half-life of the tuftsin sequence to a clinically useful window. It holds Russian regulatory approval as a prescription anxiolytic for generalized anxiety disorder and asthenic conditions. It is not approved by the FDA, EMA, or other Western regulators, and the supporting trial literature is predominantly Russian-language. Outside Russia and a few CIS countries, Selank sits in the research-peptide grey market. Users tend to be biohackers seeking benzodiazepine-alternative anxiolysis, students or knowledge workers chasing calm-focused cognition, and a smaller cohort using it for adjunctive treatment of anxiety symptoms outside formal psychiatric care. ## Mechanism of action Selank's pharmacology is incompletely characterized. The heptapeptide modulates GABAergic, serotonergic, and dopaminergic signaling, and increases brain-derived neurotrophic factor (BDNF) expression in hippocampal neurons in rodent models. It also engages the tuftsin-like immunomodulatory pathway, modulating enkephalin levels and cytokine signaling. Unlike benzodiazepines, Selank does not directly bind GABA-A receptors, which is consistent with its anxiolytic effect occurring without the sedation, ataxia, or dependence profile of that class. Plasma half-life is approximately 30 minutes, but behavioral effects in preclinical models persist well beyond the plasma window, indicating downstream signaling persistence. The exact receptor target has not been definitively identified. Onset after intranasal dosing is rapid, with anxiolytic effects detectable within 15 to 30 minutes and persisting for several hours. ## Evidence base The Russian literature contains a handful of randomized clinical trials, most of which have not been independently replicated in Western settings. Zozulia 2008 (n=62, GAD patients) compared Selank intranasal at 2.7 mg/day for 14 days against medazepam and reported comparable reductions in Hamilton Anxiety Rating Scale (HAM-A) scores, with Selank showing better tolerability and no rebound anxiety on discontinuation. Kozlovskaia 2003 reported similar anxiolytic efficacy in adjustment disorder with anxious mood. A Medvedev 2014 review summarized 10 to 14 day Russian intranasal protocols across roughly 200 patients and described consistent HAM-A reductions of 30 to 50% versus baseline. Cognitive endpoints (reaction time, attention) showed modest improvements in asthenic conditions, though these were not the primary outcomes. Preclinical work is more abundant. Russian labs have published rodent studies showing increased BDNF in hippocampus and frontal cortex, neuroprotection in ischemia models, and modulation of monoaminergic neurotransmission. The mechanistic and behavioral preclinical literature is the strongest part of the evidence base; the clinical literature is structurally weaker due to small sample sizes, single-language publication, and absent Western replication. Long-term safety data is limited to short-course Russian trial windows of 10 to 14 days. There is no published evidence on chronic use beyond a few weeks, and no Western pharmacovigilance database to draw on. The honest framing for Western users is that Selank has plausible mechanism, modest short-course efficacy in Russian trials, and unknown long-term safety. ## Dosage and administration The standard Russian clinical route is intranasal spray, dosed 250 to 500 mcg per nostril, 2 to 3 times daily, for total daily doses of 1.5 to 3 mg. A typical 14-day course is the longest validated window. Anecdotal Western users sometimes use subcutaneous routes at 100 to 300 mcg, which has no clinical validation but is reported to produce similar effects. Intranasal sprays are usually formulated at 0.15% (1.5 mg/mL); 2 to 3 sprays per nostril delivers approximately 200 to 300 mcg per side. Alcohol-free saline-based sprays are preferred for nasal mucosal tolerability. Anecdotal cycling protocols run 10 to 14 days on, then a similar washout, mirroring the Russian short-course pattern. There is no Western-validated cycling data. Reference the existing typicalDoseMg of 0.4 (representing the per-administration dose, not daily total) and the 2 to 3 times daily intranasal frequency as starting orientation. ## Side effects and safety Reported adverse effects are mild: nasal mucosal irritation from intranasal use, transient drowsiness in a small fraction of users, and mild headache. Russian RCTs report no physical dependence with short-course use and no rebound anxiety on discontinuation, in contrast to benzodiazepines. Contraindications include pregnancy, lactation, and severe psychiatric disorder where peptide pharmacokinetics and downstream effects have not been studied. Interactions are sparsely documented: concurrent benzodiazepines may produce additive anxiolytic effect with potential for over-sedation, and SSRI co-administration is described in Russian protocols without documented adverse interaction. The compound is not on the WADA Prohibited List as of 2026, though athletes should verify current status before competition. ## Practical notes Lyophilized vials and pre-formulated nasal sprays should be refrigerated. Reconstituted intranasal solution is typically stable for 30 days refrigerated. Light-protection is sensible but not strictly required. Expect anxiolytic effect within 15 to 30 minutes of an intranasal dose, peaking around 1 hour, with a useful window of several hours. Cognitive and mood effects accumulate modestly over a 10 to 14 day course; users describe a quieter internal monologue, reduced anticipatory anxiety, and steadier mood without sedation. Selank is frequently paired with Semax in Russian nootropic stacks, with the rationale of non-overlapping mechanisms (Selank for anxiolysis, Semax for activation), though there is no controlled human data on the combination. Set realistic expectations: a peptide validated only in small Russian short-course trials is not a substitute for evidence-based treatment of moderate or severe anxiety disorders.